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Alzheimer’s disease (AD), Parkinson’s disease (PD), and cancer (e.g., leukemia) are the most devastating disorders aﬀecting
millions of people worldwide. Except for some kind of cancers, no eﬀective and/or deﬁnitive therapeutic treatment aimed to
reduce or to retard the clinic and pathologic symptoms induced by AD and PD is presently available. Therefore, it is urgently
needed to understand the molecular basis of these disorders. Since oxidative stress (OS) is an important etiologic factor of the
pathologicprocessofAD,PD,andcancer,understandinghowintracellularsignalingpathwaysrespondtoOSwillhaveasigniﬁcant
implication in the therapy of these diseases. Here, we propose a model of minimal completeness of cell death signaling induced
by OS as a mechanistic explanation of neuronal and cancer cell demise. This mechanism might provide the basis for therapeutic
design strategies. Finally, we will attempt to associate PD, cancer, and OS. This paper critically analyzes the evidence that support
the “oxidative stress model” in neurodegeneration and cancer.
1. The Verdict: Oxygen Is Guilty,Not Guilty
Oxidative stress (OS) has become a major topic in all areas
of medical knowledge. Entry of the term “oxidative stress” in
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) shows that
the number of publications has dramatically increased from
none in the early 1970’s to cover ∼90,000 peer-reviewed
articles in 2011 (Figure 1(a)). A similar trend is recorded
for Alzheimer’s disease (AD), Parkinson’s disease (PD), and
cancer when searched jointly with OS (Figure 1(b)). Since
the discovery of the superoxide dismutase (SOD) in 1969 by
McCord and Fridovich ([1], for a historical perspective see
[2–4]), our understanding of the molecular defense mech-
anisms, which include catalase [5], glutathione peroxidase
(GPx), and peroxiredoxin [6] and thioredoxin reductase
[7], against diverse stress stimuli and pathogens [8]h a s
dramatically changed (reviewed in [9, 10]). Moreover, given
the phylogenetic distribution and subcellular localization of
theSODisozymes,thediscoveryhasprovidedstrongsupport
for the hypothesis that the chloroplasts and mitochondria
of eukaryotic cells arose from prokaryotic endosymbionts
[11]. SOD is an enzyme that catalyzes the dismutation of
the superoxide radical (O2
·−)v e r ye ﬃciently (k2 ∼ 2 ×
109M
−1s−1) through a redox reaction of its copper centre
enzyme into oxygen (O2) and hydrogen peroxide (H2O2).
Today, it is clear that decrease of enzymatic activity of the
defense system or an overwhelming production of O2
·−
and/or H2O2 is linked to neurodegenerative disorders (e.g.,
familial amyotrophic lateral sclerosis [12], AD [13], PD
[14], and cancer [15]). The idea that oxygen might not
only be involved in the beginning of life and evolution
[16–18] but also it might be a toxic molecule [19]w a s
further popularized by Halliwell and Gutteridge in their
book entitled “Free Radicals in Biology and Medicine”
[20] and some important follow-up papers [21–23]. The
chemistry of oxygen is well known. Basically, O2 is classiﬁed
as a free radical. By deﬁnition, a free radical is an atom
or group of atoms with at least one unpaired electron.
Indeed, the electronic conﬁguration of the oxygen diatom
is [2He4]2s42p8 with the ﬁrst ten electrons placed into σ,
σ∗, π, orbitals, and two unpaired electrons each located in
ad i ﬀerent π∗ antibonding orbital. Removal of an electron2 Oxidative Medicine and Cellular Longevity
from O2 results in a superoxide cation radical (O2
·+). In
contrast, if a single electron is added, the product is the
superoxide anion radical (O2
·−). Addition of one more
electron will yield the peroxide ion, O2
2−, which is not
a radical. Since this reaction may take place in solution,
it is quite likely that this ion became protonate (2H+)
and converted into H2O2. This last compound represents
a potential danger. In the presence of metal ions such as
iron (Fe2+)a n dc o p p e r( C u +), H2O2 decomposes into more
reactive free radical specie, the hydroxyl radical (·OH). In
sharp contrast with O2
·−, there is not an antioxidant system
to protect cells against ·OH. Indeed, this last radical can
provoke a whole series of radical chain reactions involving
damage of lipids, proteins, and nucleic acids. Therefore, an
excessive generation or accumulation of O2
·−/H2O2 may
lead to a biochemical phenomenon known as OS. Simply,
this term refers to an atypical state in which exaggerate
production of reactive species overwhelms the antioxidant
defense systems of the cell [24]. Interestingly, O2
·− and
H2O2 are recognized to play signaling functions (reviewed
in [25, 26]). However, H2O2 best fulﬁlls the requirements of
being a second messenger, that is, its enzymatic production,
along with the requirements for the oxidation of thiols
by this molecule, provides the speciﬁcity for time and
place that are required in signaling, whilst O2
·− is more
likely as a precursor of H2O2. Although eﬀorts have been
made to explain the complexities of OS in cancer [27,
28] and neurodegeneration [29–31], several questions still
remain unanswered, mainly because of two key issues. First,
except for a few causative genetic mutations, the underlying
pathogenic mechanism(s) of Parkinson’s and Alzheimer’s
cases is not yet well understood. Consequently, this makes
it diﬃcult to identify potential therapeutic targets to stop
their progression. Therefore, it is imperative to elucidate
the precise molecular mechanism and/or identify the molec-
ular “switches” that trigger neuronal death [32]. Clearly,
identifying the precise steps/“switches” in the pathological
cascade has been proven diﬃcult since multiple death
signaling pathways are often activated in response to a
single stimulus. Thus, the questions what kills neurons and
how do they get deteriorate in neurodegenerative diseases
[33, 34] are still unresolved. Second, it is not surprising
that some neuroprotective clinical trials had been completely
unsatisfactory [35–38]. This last outcome is even aggravated
by either technical incongruities [39], the challenging task of
recruitment and retention of subjects in clinical trials (e.g.,
AD, [40]), limited knowledge on antioxidant bioavailability
[41, 42], or that they have failed because they have not been
aimed at the right target [43–45].
2. The Bad Touch of OxidativeStress:
Involvement in Alzheimer’s and Parkinson’s
Disease
AD and PD are the two most common progressive neu-
rodegenerative disorders worldwide [46, 47]a ﬀecting all
ethnicities but especially some genetically isolated groups,
suchasthe“paisacommunity”livingintheAntioquiaregion
of Colombia [48–52]. AD and PD are neuropathologically
characterized by abundant insoluble protein deposits (e.g.,
Aβ[1–40/42] and hyperphosphorylated tau in AD [53], α-
S y n u c l e i ni nP D[ 54], metal deposition (e.g., iron [55–
57]), speciﬁc neuronal and synaptic loss of the hippocampal
pyramidal neurons (AD), and dopaminergic neurons of
the substantia nigra (PD), probably via OS [58]. Despite
the fact that both of these types of cells are vulnerable
to OS, it is still unknown the complete cascade of molec-
ular events at a single cell level responsible for neural
deterioration. Consequently, no eﬀective and/or deﬁnitive
therapeutic treatment aimed at reducing or delaying clinical
and pathological symptoms is currently available. Therefore,
it is urgently needed to elucidate the molecular cell death
signaling pathway involved in these processes to identify
potential pharmacological target(s).
To get insight into these issues, we initially selected
peripheral blood lymphocyte (PBL) culture as model system
in AD and PD. Indeed, these cells display striking biochem-
ical similarities to neurons (e.g., [59–63]). Lymphocytes
therefore represent a remarkable nonneural cell model
for understanding the molecular machinery and metabolic
regulation of apoptosis associated with cell survival signaling
against stressful stimuli. Apoptosis is a controlled and
regulated form of programmed cell death deﬁned by speciﬁc
morphological features such as rounding-up of the cell,
reduction of cellular volume, chromatin condensation (i.e.,
stage I nuclei morphology composed of high molecular
weight DNA), nuclear fragmentation (i.e., stage II nuclei
morphologycomposedoflowmolecularweightDNA,highly
chromatin condensation packed in round masses),classically
little or no ultrastructural modiﬁcations of cytoplasmic
organelles, and plasma membrane blebbing [64]. Although
morphologically similar, apoptosis can be triggered through
diﬀerent intrinsic or extrinsic signaling biochemical routes
[65–67]. Because H2O2 i sm o r es t a b l er e a c t i v eo x y g e n
specie (ROS), it can work either as a second messenger
in prosurvival [68] or in prodeath intracellular signaling
pathways. During the last decade, we have focused on inves-
tigating the H2O2-induced cell death signaling in PBLs. We
have consistently shown that Aβ[25–35] [69], dopamine (DA,
[70]), and its related neurotoxins (e.g., 6-hydroxidopamine
(6OHDA), 5,6 and 5,7-dyhydroxy-tryptamine (5,6- and -
5,7-DHT, [71]), paraquat (PQ, [72]), and rotenone (ROT,
[73]) induce apoptosis in lymphocytes in a concentration-
and time-dependent fashion by OS mechanism involving
several steps: O2
·− and H2O2 generation (Figure 2,s t e p1 ,
numbers in red), activation of the nuclear factor kappa-B
(NF-κB, step 2)/p53 (step 3)/c-Jun N-terminal kinase (JNK,
step 4)/c-Jun (step 5) transcription factors, mitochondrial
depolarization (step 6), and caspase-3 activation (step 7).
As a result we observed the typical nuclei morphologi-
cal feature of apoptosis including chromatin condensation
and fragmentation (step 8). Remarkably, this cell death
subroutine can be blocked by the action of antioxidants
(e.g., N-acetyl-cysteine (NAC) [69, 71], vitamin C (VC,
[71]), testosterone [70], 17β-estradiol [70, 74], cannabinoids
(e.g., CP55940 and JWH-015 [72, 75]), mitochondria per-
meabilization transition pore inhibitor (e.g., cannabinoidsOxidative Medicine and Cellular Longevity 3
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Figure 1: Number of articles reported in PubMed by using the term “oxidative stress” (OS) alone (a) or together (b) with the term
“Parkinson” (P), “Alzheimer” (A), and “cancer”.
[76]), insulin-like growth factor-1 [72, 73, 77]), high glucose
[72, 73], speciﬁc pharmacological inhibitors (e.g., PDTC,
piﬁthrin-α, SP600125, Ac-DEVD-cho inhibitor of NF-κB,
p53, JNK, and caspase-3, resp.) and inhibitors of protein
(e.g., cycloheximide [71]), and RNA (e.g., actinomycin D
[69, 71]) synthesis. These ﬁndings may be explained by the
following assumptions. H2O2 might indirectly activate NF-
κBthroughphosphorylationoftheIκBα(i.e.,theinhibitorof
the complex NF-κB or p50/p62) either by the spleen tyrosine
kinase protein (Syk, step 9, number in blue) at tyrosine 42
[78, 79]o ra ts e r i n e3 2a n d3 6v i aS H 2( S r ch o m o l o g y
2)-containing inositol phosphatase-1 (SHIP-1, step 10)/IκB-
kinase (IKK) complex pathway [80]. Alternatively, H2O2
might activate NF-κB through activation of the IKK complex
by mitogen-activated protein kinase/ERK kinase kinase-1
(MEKK1, step 11, [81]). Once the IκB is phosphorylated,
the release of active NF-κB dimmer (p50/p63) translocates
into the nucleus and transcribes several antiapoptotic genes
(e.g., Bcl-2, cIAP-1-2, and Bcl-xL) (step 12) and pro-
apoptotic genes, amongst them the p53 [82]. At this point,
a vicious cycle is established wherein p53 plays a critical
role by balancing the cell to a death decision because of
its many actions. First, p53 transcribes proapoptotic genes
such as Bax (step 13), which in turn might contribute to
the permeabilization of the outer mitochondrial membrane
by antagonizing antiapoptotic proteins (e.g., Bcl-2, cIAP-1-
2, and Bcl-xL). Second, p53 not only induces prooxidant
genes (e.g., p53-induced gene-3 (PIG3), proline oxidase (PO),
step 14), which generate more H2O2 but also represses the
transcription of antioxidant genes (e.g., NAD(P)H: quinone
oxidoreductase-1)[ 83]. Elevated stress stimuli (i.e., H2O2
production, step 1) and further activation of NF-κB induce
upregulation of proapoptotic genes (e.g., p53), which in
turn amplify the initial H2O2-induced cell death signal.
Formation of the mitochondrial permeabilization transition
pore allows the release of apoptogenic proteins (by a not
fully established mechanism, step 15 [84, 85]) such as
the apoptosis-inducer factor (AIF, [86]) responsible for
causing DNA fragmentation and chromatin condensation
(i.e., stage I nuclei morphology) and cytochrome C, which
together with Apaf 1, dATP, and procaspase-9 (i.e., the
apoptosome) elicits caspase-3 protease activation [87]. This
protease is essential for the fragmentation and morphologi-
cal changes associated with apoptosis [88]. Indeed, caspase-
3 activates the endonuclease DNA fragmentation factor 40
(DFF40) or caspase-activated DNAse (CAD) by cutting the
nuclease’s inhibitor DFF45/ICAD [89]. Finally, DFF40/CAD
causes nuclear chromatin fragmentation (i.e., stage II nuclei
morphology), typical of apoptosis [90]. Interestingly, the
apoptosis signal-regulating kinase (ASK1; step 16, [91]) and
MEKK1 (step 11, [92]) phosphorylate MKK4/MAPK kinase
(step 17). MEKK1 kinase therefore represents a cross-talk
between the JNK and NF-κB pathway. Indeed, MEKK1
kinasephosphorylatesIKKandMKK4.Thislastkinasephos-
phorylates JNK/stress apoptosis protein kinase (SAPK [93],
step 4), which in turn phosphorylates the c-Jun transcription
factor [94], also involved in transcription of death signaling
[95]. Interestingly, it has also been shown that JNK1/2
cooperates in the activation of p53 apoptotic pathway [96,
step 3]. Alternatively, high concentration of metal ions (e.g.,
Fe2+;C u +,M n 2+) alone or in combination with H2O2 are
able to directly induce mitochondria damage and apoptotic
morphologybycaspase-3-dependentmechanism[70,97].In
conclusion, NF-κB, p53, c-Jun and caspase-3 activation, and
mitochondrial depolarization are crucial events in mediating
cell death by apoptosis.4 Oxidative Medicine and Cellular Longevity
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Figure 2: Proposed model of minimal completeness of cell death signaling induced by oxidative stress as a mechanistic explanation of
neuronal and cancer cell demise.The neurotoxins Aβ[25–35], dopamine (DA) and its related neurotoxins (6OHDA, 5,6- and 5,7-DHT),
paraquat(PQ),androtenone(ROT)triggeracelldeathsubroutineinlymphocytes,awell-establishedmodelofADandPD.Thismechanism
is characterized by O2
·−/H2O2 generation (step 1, numbers in red), activation of the transcription factors NF-κB( s t e p2), p53 (step 3), and c-
Jun (step 5), activation of the JNK kinase (step 4), mitochondrial depolarization (step 6), caspase-3 activation (step 7), and nuclei chromatin
condensation/fragmentation (step 8). These ﬁndings may be explained by the following assumptions. H2O2 might indirectly activate NF-κB
through phosphorylation of its inhibitor IκBα either by Syk (step 9, numbers in blue)o rv i aS H I P - 1( s t e p10)/IKK complex pathway. H2O2
might also activate NF-κB through activation of the IKK complex by the MEKK1 protein (step 11). Once NF-κBi sa c t i v a t e d ,i tt r a n s l o c a t e s
into the nucleus and transcribes several antiapoptotic genes (step 12) and proapoptotic genes, amongst them thep53 (step 3). At this point, a
vicious cycle is established. First, p53 transcribes proapoptotic genes such as Bax (step 13), contributing to the permeabilization of the outer
mitochondrial membrane by antagonizing antiapoptotic proteins. Second, p53 induces prooxidant genes (e.g., p53-induced gene-3 (PIG3),
prolineoxidase(PO),step14),whichgeneratemoreH2O2 (step1)andrepressesthetranscriptionofantioxidantgenes.H2O2 overproduction
and further activation of NF-κB induce upregulation of proapoptotic genes (e.g., p53), which in turn amplify the initial H2O2-induced
cell death signal (step 2–8). Mitochondrial damage allows the release of apoptogenic proteins (step 15) responsible for the formation of
apoptosome and activation of caspase-3 protease. This protease in turn activates the endonucleases DFF40/CAD, by cutting the nuclease’s
inhibitorDFF45/ICAD.Finally,DFF40/CADcausesnuclearchromatinfragmentation,typicalofapoptosis.Alternatively,ASK1(step16)and
MEKK1 (step 11) phosphorylate MKK4/MAPK kinase (step 17). MEKK1 kinase also phosphorylates IKK. This last kinase phosphorylates
JNK1/2/SAPK (step 4), which in turn phosphorylates c-Jun, also involved in death signaling. Noticeably, vitamin C (VC) and vitamin K3
(VK3) alone or in combination induce apoptosis in Jurkat and K562 cells by a similar mechanism as described. This mechanism might
provide the basis for therapeutic design strategies in AD, PD, and cancer (leukemia).Oxidative Medicine and Cellular Longevity 5
Over the years, not only in vitro (e.g., [98–107]o r
in situ (e.g., [55, 108–115]) but also in vivo studies have
validated the ﬁndings highlighted in Figure 2,s t e p1 – 8 .
Of note, McLellan et al. [116] have shown directly that
a subset of amyloid plaques (e.g., dense core plaques)
produce ROS, that is, H2O2, in animal Alzheimer’s models
(e.g., Tg2576 APP overexpressing transgenic mice) and in
human postmortem Alzheimer tissue. Wang et al. [117]
found that Aβ[1–42] injection in Sprague-Dawley male rats
increased JNK and NF-κB protein levels in brain. This
eﬀect was prevented by hydrogen-rich saline implicating
OS. Likewise, Mogi et al. [118, 119] showed signiﬁcant
increase in the levels of p53, NF-κB, and caspase-3 reﬂecting
apoptosis in the Parkinsonian brain. In agreement with
these human brain data, Liang et al. [120] have shown
that NF-κB activation contributes to 6-OHDA OS-induced
degeneration of dopaminergic neurons through a NF-κB-
dependent p53-signaling pathway in rat model of PD.
Interestingly, Li et al. [121] have shown that bilobalide (an
activecomponentofGingkobiloba)andthepeptideinhibitor
of NF-κB, SN50 inhibit 6-OHDA-induced activation of NF-
κB and loss of dopaminergic neurons in rat substantia nigra.
Mu˜ noz et al. [122] have shown that systemic administration
of NAC protects dopaminergic neurons against 6-OHDA-
induced degeneration in rats. Remarkably, Braithwaite et
al. [123] have shown that SP600125 inhibition of JNK
provides neuroprotection in a Tg2576/PSm146L transgenic
mice model of AD. To establish in vivo relevance of our
in vitro ﬁndings, we showed that SP600125 increased the
survival and locomotor activity of Drosophila melanogaster
(D. melanogaster [124]), used as a valid model of PD [125,
126], against acute exposure to PQ [127]. Furthermore,
the cannabinoid CP55,940 prolongs survival and improves
locomotor activity in Drosophila against acute exposure to
PQ [124]. We also demonstrated that pure polyphenols such
as gallic acid (GA), ferulic acid (FA), caﬀeic acid (CA),
coumaric acid (CouA), propyl gallate (PG), epicatechin
(EC), epigallocatechin (EGC), and epigallocatechin gallate
(EGCG) protect, rescue, and, most importantly, restore
the impaired movement activity (i.e., climbing capability)
induced by PQ in the ﬂy [128]. Remarkably, PG and
EGCG protected and maintained movement abilities in ﬂies
cotreated with PQ and iron [128]. Recently, Ortega-Arellano
et al. [129] have demonstrated that chronic polyphenols
prolong life span and restore locomotor activity of D.
melanogaster chronically exposed to PQ compared to ﬂies
treated with PQ alone. These observations support the
notion that polyphenols might be potential therapeutic
compounds in the treatment of PD [130, 131]. Moreover,
Bonilla-Ramirez et al., [132] have found that desferrioxam-
ine (DFO), ethylenediaminetetraacetic acid (EGTA), and D-
penicillamine chelators were able to protect but not rescue
D. melanogaster against acute or chronic metal intoxication.
Taken together, in vitro and in vivo data suggest that
antioxidants (e.g., NAC [133]), polyphenols, cannabinoids,
metal chelators [134], mitochondrial targeted antioxidant
compounds [135, 136], pharmacological inhibition of NF-
κB[ 137, 138], p53 [139, 140], JNK [141], and caspase-3 may
b eo ft h e r a p e u t i cv a l u ei nA Da n dP D .
3. The GoodTouch of OxidativeStress:
A Perspective for Cancer Cell Death
Oxidative stress has two opposite outcomes in cancer cells:
on one side, OS has been associated to initiation, promotion,
progression, and maintenance of tumor cell phenotypes [26,
27]. Speciﬁcally, H2O2 stimulates proliferation, migration,
andadhesionofthesecells[142–144].However,thecausative
relationship of ROS increase, and oncogene activation
remains unclear. On the other side, OS has been associated
with antitumorigenic actions, senescence, and apoptosis
[145, 146]. Strikingly, NF-κB has been found to play pro-
and antiapoptotic roles, which might depend on the type
of cell [147–151], intracellular level of ROS, induced or
constitutive expression of NF-κB, quantity of cellular antiox-
idant defenses, and absence or presence of growth factors or
metabolic sources (e.g., glucose). Therefore, NF-κBc o n s t i -
tutes a critical molecule in cell survival/death decision. Based
on our previous experience with OS mechanism and cell
death, we hypothesize that cancer and neurodegeneration
processes share common cellular foundations. In contrast
to the unsatisfactory results of the antioxidant therapy in
AD [152, 153]a n dP D[ 154], generation of ROS to kill
cancer cells is currently not only an idea but has already been
eﬀective as treatment in cancer patients (e.g., procarbazine,
doxorubicin, and arsenic). We reasoned that the OS mech-
anism depicted in the Figure 2 might be operative in both
neurodegeneration and cancer processes but with opposite
therapeutic approaches: while it might be used to destroy
malignant cells, it might also be stopped with antioxidants
or signals to retard or delay neural cell death. Concerning
the former consideration, we found that low-dose (10μM)
vitamin K3 (VK3, also known as menadione or 2-Methyl-
1,4-naphthoquinone) or high-dose (10mM) vitamin C (VC,
also known as ascorbate, AscH−) alone or in combination
induced apoptosis in Jurkat (model of acute lymphoblastic
T-cell leukemia [155]) and K562 (model of myelogenous
leukaemia cells) cells by OS mechanism [156]. This data
provided, for the ﬁrst time, in vitro evidence supporting a
causative role for OS in VK3- and VC-induced apoptosis in
Jurkat and K562 cells in a domino-like mechanism similar
to the mechanism identiﬁed in lymphocytes and neuronal
cells under OS (Figure 2). The VC/VK3 observations can
be explained because the synthetic VK3 can be reduced via
one- or two-electron transfer by intracellular reductases or
by VC. The two electron reductions of VK3 to hydroquinone
VK3 (VK3QH2) can slowly autoxidise to reform VK3. The
single-electron reduction of the VK3 by VC− (AscH−)g i v e s
semiquinone anion radical (VK3Q
·−), which in turn reduces
O2 to O2
·− and regenerates the VK3. Consequently, redox
cycling of VK3 can ensue and produce large amounts of
O2
·−, which can dismutate via SOD to form H2O2 and
O2.A sm e n t i o n e d ,H 2O2 can take part in metal-catalyzed
reactions to form more toxic species of active oxygen
such as ·OH. Therefore, if the single-electron reduction
pathway predominates and the rate of redox cycling of
VK3 exceeds the capacity of the detoxifying enzymes (e.g.,
catalase, GPx, and SOD), OS occurs, ultimately triggering
a speciﬁc subroutine of cell death signaling (Figure 2 and6 Oxidative Medicine and Cellular Longevity
[156]). Altogether these data suggest that VK3 and VC or
any molecule capable of producing excessive amount of
O2
·−/H2O2 can be useful in the treatment of leukemia (e.g.,
arsenic [157], taxol [158]).
4.Dangerous Liaisons:OxidativeStress as
Central Aspect for Neurodegeneration and
Cancer
Up-to-date, >200 pathogenic mutations distributed in 3
(Aβ amyloid precursor protein (APP), presenilin-1 (PSEN1),
presenilin-2 (PSEN2)), and 6 genes (α-Synuclein (SNCA),
Leucine-rich repeat kinase 2 (LRRK2), PARKIN, PTEN-
i n d u c e dp u t a t i v ek i n a s e1(PINK1), DJ-1,a n dP-type
ATPase 13A2 (ATP13A2)) have been conclusively shown
to cause familial Alzheimer and Parkinsonism, respectively
(http://www.molgen.ua.ac.be, reviewed in [159, 160]). Inter-
estingly, mutations in those genes are directly related to OS
and mitochondrial alterations [161, 162]. Speciﬁcally, Vinish
et al. [163] have found increase in malondialdehyde content
and SOD activity in peripheral blood parameters in PD
patients with PARKIN mutations in comparison to controls.
Ramsey and Giasson [164] found that the p.E163K DJ-1
mutant loses the ability to protect against OS while demon-
strating a reduced redistribution towards mitochondria.
Moreover, Ren et al. [165] have shown that DJ-1 protects
cells against UVB-induced cell death dependent on its
oxidation and its association with mitochondrial Bcl-X(L).
Heo et al. [166] have shown that the p.G2019S mutation
in LRRK2 generates H2O2 and induces neurotoxicity via
its kinase activity. Last, the Butterﬁeld’s group has shown
that mutation in APP and PSEN1 (e.g., APPNLH/PS-1P264L
mice)inducesbrainOS[167,168].Takentogether,thesedata
support the notion that environmental and genetic pathways
converge in the pathogenesis of AD [169]a n dP D[ 170–172].
It is interesting to note that iron accumulation is linked with
the brain pathology in AD [55] and familial PD [56, 57].
These observations suggest that iron might play a toxic
role in the pathophysiology of both neurologic disorders
[173, 174], most probably linked to a common molecular
mechanism of cell death via generation of intermediate ROS
andmitochondrialdamage[97,175,176].Therefore,itisnot
unusual that PD patients develop dementia [164, 177, 178]
concomitantly with AD pathology [179]. Moreover, recent
data suggest that exposition to ethacrynic acid, a compound
that induces cellular glutathione (GSH) depletion therefore
causing OS, increases presenilin-1 protein levels in human
neuroblastoma SH-SY5Y cells [180]. Furthermore, the γ-
secretase protein complex mediates OS-induced expression
of β-site APP cleaving enzyme I (BACE1) resulting in
excessive Aβ production in AD [181]. Remarkably, extensive
analysis of the eﬀects and interactions of the AD [182, 183]
and PD [184, 185] pathogenic genes in D. melanogaster
has shown that mutations in parkin [186, 187], pink-1
[188], α-synuclein [189], Lrrk [190] genes, or overexpression
of normal α-synuclein [189] cause death of dopaminergic
neurons in Drosophila probably via OS [166, 191–195].
Accordingly, it has been shown that DJ-1 and parkin are
essential for mitochondrial function and rescue pink-1 loss
of function [196, 197]. Since these genes are conserved in
invertebrates (insects) and vertebrates (mammals) [198],
we believe that D. melanogaster could provide new insights
into the relationship between gene mutations, OS, and
mitochondria [184]. Taken together, these data suggest that
OS is at the pathobiological basis of PD and AD and that
its generation and detrimental eﬀects can be exacerbated by
environmental factors and mutation in causative genes.
Surprisingly, epidemiological studies have consistently
shown the cooccurrence of PD and melanoma [199, 200]
and this association is strongly increased by mutations
in PARKIN, LRRK2,a n dα-Synuclein (for a review, see
[201]). Moreover, Veeriah et al. [202] have shown that point
mutations and exon rearrangements of PARKIN are linked
to glioblastoma multiform, colon cancer, and lung cancer.
Although, the exact mechanism(s) underlying the observed
cancer-PD association is not clear, it has been suggested
that genes (e.g., PARKIN) that cause neuronal dysfunction
when mutated in the germline may instead contribute to
oncogenesis when altered in nonneuronal somatic cells
[202]. Whether OS is involved in these malignancies needs
further investigation. However, based on the assumption
that cancer and neurodegeneration share some of the same
genes and molecular mechanisms of OS-induced cell death,
one may anticipate a positive correlation between OS,
cancer and PD. Recently, Zhang et al. [203]h a v ef o u n d
that Parkin is a p53 target and Parkin contributes to
the role of p53 in regulating antioxidant defense. Indeed,
ectopic Parkin expression signiﬁcantly reduced ROS levels in
H460p53siRNA treatedwithorwithoutH2O2.Simultaneous
knockdown of p53 and Parkin results in higher intracellular
ROS levels than individual knockdown of p53 and Parkin.
Moreover, ectopic Parkin expression signiﬁcantly increased
GSH (reduced) levels, thus altering the GSH:GSSG (oxi-
dized) ratio in human lung cancer line, H460p53siRNA.
Interestingly, Parkin knockdown in H460 (control) cells and
Parkin knockout in mouse embryonic ﬁbroblast (MEF) cells
signiﬁcantly decreased GSH levels and the GSH:GSSG ratio.
GiventhatParkinhasalsobeenreportedtorepressp53[204],
together these data suggest that the regulation of Parkin by
p53,orvicev ersa,couldbecelltypeortissuespeciﬁc.F urther
investigation is warranted in this topic.
5. OxidativeStress:Quo Vadis?
In conclusion, there is enough support evidence for the
role of OS in AD, PD, and cancer. Clearly, the relationships
betweensomecausativegenesofParkinson’ssuchasPARKIN
and LRRK2 and cancer will challenge the medical research
for designing new therapeutic approaches and the necessity
to bring new proposals of uniﬁed models of disease and
molecularmechanisms.Inthisrespect,themodelofminimal
completeness of cell death induced by H2O2 (see Figure 2,
steps 2–8) might provide a platform to evaluate new natural
or synthetic antioxidants, pharmacological agents which
target the mitochondria, transcription factor(s), and/or
caspase-3, or it simply might be used as a model to test
other novel hypothesis (e.g., [205, 206]). In this regard,Oxidative Medicine and Cellular Longevity 7
plant polyphenols has been suggested as promising com-
pounds for the prevention of neurodegenerative diseases and
treatment of cancer (For reviews see [130, 207–209]). Yet,
whether polyphenols might function as eﬀective antioxidant
compounds in vivo is still a controversial issue [210–213].
One of the most urgent issues is to clarify the many
studies reported to show failed clinical beneﬁt or persuasive
evidence of neuroprotection [214]. Most importantly, we
will need to deﬁnitely establish the molecular mechanism(s)
of cell death in neurodegenerative disorders before novel
treatments can be available. Undoubtedly, there are still
many unresolved issues. Perhaps, studying the biology of
cancer cells might provide understanding of the underlying
pathogenic mechanisms of cell death in neurodegeneration
and help developing new treatment strategies.
Acknowledgments
The work was supported by Colciencias (Grant
#111534319119, 111540820504, and 111540820525) and
UdeA (Grant #8780).
References
[1] J. M. McCord and I. Fridovich, “Superoxide dismutase.
An enzymic function for erythrocuprein (hemocuprein),”
Journal of Biological Chemistry, vol. 244, no. 22, pp. 6049–
6055, 1969.
[2] J. M. McCord and I. Fridovich, “Superoxide dismutase: the
ﬁrst twenty years (1968–1988),” Free Radical Biology and
Medicine, vol. 5, no. 5-6, pp. 363–369, 1988.
[3] I. Fridovich, “With the help of giants,” Annual Review of
Biochemistry, vol. 72, pp. 1–18, 2003.
[4] N. Kresge, R. D. Simoni, and R. L. Hill, “Forty years of
superoxide dismutase research: the work of Irwin Fridovich,”
The Journal of Biological Chemistry, vol. 281, pp. e17–e19,
2006.
[5] M. M. Goyal and A. Basak, “Human catalase: looking for
complete identity,” Protein and Cell, vol. 1, no. 10, pp. 888–
897, 2010.
[6] L. Floh´ e, S. Toppo, G. Cozza, and F. Ursini, “A comparison
of thiol peroxidase mechanisms,” Antioxidants and Redox
Signaling, vol. 15, no. 3, pp. 763–780, 2011.
[7] A. Holmgren and J. Lu, “Thioredoxin and thioredoxin
reductase: current research with special reference to human
disease,” Biochemical and Biophysical Research Communica-
tions, vol. 396, no. 1, pp. 120–124, 2010.
[8] T. L. Leto and M. Geiszt, “Role of Nox family NADPH
oxidases in host defense,” Antioxidants and Redox Signaling,
vol. 8, no. 9-10, pp. 1549–1561, 2006.
[9] A.D’alessandroandL.Zolla,“TheSODyssey:superoxidedis-
mutasesfrombiochemistry,throughproteomics,tooxidative
stress, aging and nutraceuticals,” Expert Review of Proteomics,
vol. 8, no. 3, pp. 405–421, 2011.
[10] I. Batini´ c-Haberle, J. S. Rebouc ¸as, and I. Spasojevi´ c, “Super-
oxide dismutase mimics: chemistry, pharmacology, and
therapeutic potential,” Antioxidants and Redox Signaling, vol.
13, no. 6, pp. 877–918, 2010.
[11] S. C. Grace, “Phylogenetic distribution of superoxide dismu-
tase supports an endosymbiotic origin for chloroplasts and
mitochondria,” Life Sciences, vol. 47, no. 21, pp. 1875–1886,
1990.
[12] H. Aksoy, G. Dean, M. Elian et al., “A4T mutation in the
SOD1 gene causing familial amyotrophic lateral sclerosis,”
Neuroepidemiology, vol. 22, no. 4, pp. 235–238, 2003.
[13] V. Calabrese, R. Sultana, G. Scapagnini et al., “Nitrosative
stress, cellular stress response, and thiol homeostasis in
patients with Alzheimer’s disease,” Antioxidants and Redox
Signaling, vol. 8, no. 11-12, pp. 1975–1986, 2006.
[14] H. L. Martin and P. Teismann, “Glutathione - A review on its
role and signiﬁcance in Parkinson’s disease,” FASEB Journal,
vol. 23, no. 10, pp. 3263–3272, 2009.
[15] B. Popov, V. Gadjeva, P. Valkanov, S. Popova, and A.
Tolekova, “Lipid peroxidation, superoxide dismutase and
catalase activities in brain tumor tissues,” Archives of Physi-
ology and Biochemistry, vol. 111, no. 5, pp. 455–459, 2003.
[ 1 6 ] R .A .K e r r ,“ E a r t hs c i e n c e .T h es t o r yo fO 2,” Science, vol. 308,
no. 5729, pp. 1730–1732, 2005.
[17] R. A. Kerr, “Geochemistry. A shot of oxygen to unleash the
evolution of animals,” Science, vol. 314, no. 5805, p. 1529,
2006.
[18] P. G. Falkowski and Y. Isozaki, “Geology: the story of O2,”
Science, vol. 322, no. 5901, pp. 540–542, 2008.
[19] I. Fridovich, “Oxygen toxicity: a radical explanation,” Journal
of Experimental Biology, vol. 201, no. 8, pp. 1203–1209, 1998.
[ 2 0 ]B .H a l l i w e la n dJ .M .C .G u t t e r i d g e ,Free Radicals in Biology
and Medicine, Oxford University Press, New York, NY, USA,
1985.
[21] B. Halliwell, “Tell me about free radicals, doctor: a review,”
Journal of the Royal Society of Medicine, vol. 82, no. 12, pp.
747–752, 1989.
[22] B. Halliwell, “Reactive species and antioxidants. Redox biol-
ogy is a fundamental theme of aerobic life,” Plant Physiology,
vol. 141, no. 2, pp. 312–322, 2006.
[23] B. Halliwell, “Biochemistry of oxidative stress,” Biochemical
Society Transactions, vol. 35, no. 5, pp. 1147–1150, 2007.
[24] B. Halliwell and M. Whiteman, “Measuring reactive species
and oxidative damage in vivo and in cell culture: how should
you do it and what do the results mean?” British Journal of
Pharmacology, vol. 142, no. 2, pp. 231–255, 2004.
[25] H. J. Forman, M. Maiorino, and F. Ursini, “Signaling
functions of reactive oxygen species,” Biochemistry, vol. 49,
no. 5, pp. 835–842, 2010.
[26] R. Brigelius-Floh´ e and L. Floh´ e, “Basic principles and
emerging concepts in the redox control of transcription
factors,” Antioxidants and Redox Signaling, vol. 15, no. 8, pp.
2335–2381, 2011.
[27] B. Halliwell, “Oxidative stress and cancer: have we moved
forward?”BiochemicalJournal,vol.401,no.1,pp.1–11,2007.
[28] R. Visconti and D. Grieco, “New insights on oxidative
stress in cancer,” Current Opinion in Drug Discovery and
Development, vol. 12, no. 2, pp. 240–245, 2009.
[29] B. Halliwell, “Oxidative stress and neurodegeneration: where
are we now?” Journal of Neurochemistry,v o l .9 7 ,n o .6 ,p p .
1634–1658, 2006.
[30] A. Reynolds, C. Laurie, R. Lee Mosley, and H. E. Gendelman,
“Oxidative stress and the pathogenesis of neurodegenerative
disorders,” International Review of Neurobiology, vol. 82, pp.
297–325, 2007.
[31] M.Ikawa,H.Okazawa,T.Kudo,M.Kuriyama,Y.Fujibayashi,
and M. Yoneda, “Evaluation of striatal oxidative stress in
patients with Parkinson’s disease using [ 62Cu]ATSM PET,”
Nuclear Medicine and Biology, vol. 38, no. 7, pp. 945–951,
2011.
[32] T. E. Golde, “The therapeutic importance of understanding
mechanisms of neuronal cell death in neurodegenerative8 Oxidative Medicine and Cellular Longevity
disease,” Molecular Neurodegeneration, vol. 4, no. 1, article
no. 8, 2009.
[33] T. E. Golde and L. Petrucelli, “”What kills neurons in
neurodegenerative diseases?”, A review series in an open
access journal,” Molecular Neurodegeneration,v o l .4 ,n o .1 ,
article no. 7, 2009.
[34] D. J. Surmeier, J. N. Guzman, J. Sanchez-Padilla, and J. A.
Goldberg, “What causes the death of dopaminergic neurons
in Parkinson’s disease?” Progress in Brain Research, vol. 183,
no. C, pp. 59–77, 2010.
[35] C.W. Olanow, K.Kieburtz,andA.H.V.Schapira, “Why have
we failed to achieve neuroprotection in Parkinson’s disease?”
Annals of Neurology, vol. 64, supplement 2, pp. S101–S110,
2008.
[36] M. S. Raﬁi and P. S. Aisen, “Recent developments in
Alzheimer’s disease therapeutics,” BMC Medicine, vol. 7,
article no. 7, 2009.
[37] M. L¨ ohle and H. Reichmann, “Clinical neuroprotection
in Parkinson’s disease—still waiting for the breakthrough,”
JournaloftheNeurologicalSciences,vol.289,no.1-2,pp.104–
114, 2010.
[38] E. C. Lauterbach, J. Victoroﬀ, K. L. Coburn, S. D. Shillcutt,
S. M. Doonan, and M. F. Mendez, “Psychopharmacological
neuroprotection in neurodegenerative disease: assessing the
preclinical data,” Journal of Neuropsychiatry and Clinical
Neurosciences, vol. 22, no. 1, pp. 8–18, 2010.
[39] E. N. Frankel and J. W. Finley, “How to standardize the
multiplicity of methods to evaluate natural antioxidants,”
Journal of Agricultural and Food Chemistry, vol. 56, no. 13,
pp. 4901–4908, 2008.
[40] J. A. Knebl and D. Patki, “Recruitment of subjects into
clinical trials for Alzheimer disease,” Journal of the American
Osteopathic Association, vol. 110, no. 9, supplement 8, pp.
S43–S49, 2010.
[41] M. Singh, M. Arseneault, T. Sanderson, V. Murthy, and C.
Ramassamy, “Challenges for research on polyphenols from
foodsinAlzheimer’sdisease:bioavailability,metabolism,and
cellular and molecular mechanisms,” Journal of Agricultural
and Food Chemistry, vol. 56, no. 13, pp. 4855–4873, 2008.
[42] M. D’Archivio, C. Filesi, R. Var` ı, B. Scazzocchio, and R.
Masella, “Bioavailability of the polyphenols: status and
controversies,” International Journal of Molecular Sciences,
vol. 11, no. 4, pp. 1321–1342, 2010.
[43] D. E. Stevenson and R. D. Hurst, “Polyphenolic phyto-
chemicals - Just antioxidants or much more?” Cellular and
Molecular Life Sciences, vol. 64, no. 22, pp. 2900–2916, 2007.
[44] D. G. Standaert and T. A. Yacoubian, “Target validation: the
Parkinson disease perspective,” DMM Disease Models and
Mechanisms, vol. 3, no. 5-6, pp. 259–262, 2010.
[45] Y.LiuandD.R.Schubert,“Thespeciﬁcityofneuroprotection
by antioxidants,” Journal of Biomedical Science, vol. 16, no. 1,
article no. 98, 2009.
[46] Alzheimer’s Association, W. Thies, and L. Bleiler, “2011
Alzheimer’s disease facts and ﬁgures,” Alzheimer’s and
Dementia, vol. 7, no. 2, pp. 208–244, 2011.
[47] K. Wirdefeldt, H. -O. Adami, P. Cole, D. Trichopoulos, and J.
Mandel, “Epidemiology and etiology of Parkinson’s disease:
a review of the evidence,” European Journal of Epidemiology,
vol. 26, supplement 1, pp. S1–S58, 2011.
[ 4 8 ]F .L o p e r a ,A .A r d i l l a ,A .M a r t ´ ınez et al., “Clinical features
of early-onset Alzheimer disease in a large kindred with
an E280A presenilin-1 mutation,” Journal of the American
Medical Association, vol. 277, no. 10, pp. 793–799, 1997.
[49] N.Pineda-Trujillo,L.G.Carvajal-Carmona,O.Buritic´ aetal.,
“A novel Cys212Tyr founder mutation in parkin and allelic
heterogeneity of juvenile Parkinsonism in a population from
North West Colombia,” Neuroscience Letters, vol. 298, no. 2,
pp. 87–90, 2001.
[50] N. Pineda-Trujillo, M. Apergi, S. Moreno et al., “A genetic
cluster of early onset Parkinson’s disease in a Colombian
population,” American Journal of Medical Genetics, Part B,
vol. 141, no. 8, pp. 885–889, 2006.
[51] N. Pineda-Trujillo, A. D. Cepeda, W. A. P´ erez et al., “Una
mutaci´ on en el gen PARK2 causa enfermedad de Parkinson
juvenil en una extensa familia colombiana,” Iatreia, vol. 22,
no. 2, pp. 122–131, 2009.
[52] F. Barral, “Doctors explain battle to beat Alzheimer’s,” CNN,
January, 2011, http://articles.cnn.com/2011-01-27/world/
alzheimer.qa 1 alzheimer-colombian-link-disease? s=PM:
WORLD
[53] M. M. Esiri, “The neuropathology of Alzheimer’s disease,”
in Neurobiology of Alzheimer’s disease,D .D a w b a r na n dS .J .
Allen, Eds., pp. 37–58, Oxford University Press, Oxford, UK,
2007.
[54] L. S. Forno, “Neuropathology of Parkinson’s disease,” Journal
of Neuropathology and Experimental Neurology, vol. 55, no. 3,
pp. 259–272, 1996.
[55] M. A. Smith, P. L. R. Harris, L. M. Sayre, and G. Perry,
“IronaccumulationinAlzheimerdiseaseisasourceofredox-
generated free radicals,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 94, no. 18, pp.
9866–9868, 1997.
[56] M. Takanashi, H. Mochizuki, K. Yokomizo et al., “Iron
accumulation in the substantia nigra of autosomal recessive
juvenile parkinsonism (ARJP),” Parkinsonism and Related
Disorders, vol. 7, no. 4, pp. 311–314, 2001.
[57] S. A. Schneider, C. Paisan-Ruiz, N. P. Quinn et al., “ATP13A2
mutations(PARK9)causeneurodegenerationwithbrainiron
accumulation,” Movement Disorders, vol. 25, no. 8, pp. 979–
984, 2010.
[58] X. Wang and E. K. Michaelis, “Selective neuronal vulnerabil-
ity to oxidative stress in the brain,” Front Aging Neurosci, vol.
2, article 12, 2010.
[59] S. Shinde and K. Pasupathy, “Respiratory-chain enzyme
activities in isolated mitochondria of lymphocytes from
patients with Parkinson’s disease: preliminary study,” Neurol-
ogy India, vol. 54, no. 4, pp. 390–393, 2006.
[60] N. J. MacIver, S. R. Jacobs, H. L. Wieman, J. A. Woﬀord,
J. L. Coloﬀ, and J. C. Rathmell, “Glucose metabolism in
lymphocytes is a regulated process with signiﬁcant eﬀects
on immune cell function and survival,” Journal of Leukocyte
Biology, vol. 84, no. 4, pp. 949–957, 2008.
[ 6 1 ]M .C a l o p a ,J .B a s ,A .C a l l ´ en, and M. Mestre, “Apoptosis
of peripheral blood lymphocytes in Parkinson patients,”
Neurobiology of Disease, vol. 38, no. 1, pp. 1–7, 2010.
[62] D. Marazziti, G. Consoli,I.Masala, M.CatenaDell’Osso, and
S. Baroni, “Latest advancements on serotonin and dopamine
transporters in lymphocytes,” Mini-Reviews in Medicinal
Chemistry, vol. 10, no. 1, pp. 32–40, 2010.
[63] P. Feldhaus, D. B. Fraga, F. V. Ghedim et al., “Evaluation
of respiratory chain activity in lymphocytes of patients with
Alzheimerdisease,”MetabolicBrainDisease,v ol.26,no .3,pp .
229–236, 2011.
[64] G. Kroemer, L. Galluzzi, P. Vandenabeele et al., “Classiﬁca-
tion of cell death: recommendations of the NomenclatureOxidative Medicine and Cellular Longevity 9
Committee on Cell Death 2009,” Cell Death and Diﬀerenti-
ation, vol. 16, no. 1, pp. 3–11, 2009.
[65] J. C. Reed, “Mechanisms of apoptosis,” American Journal of
Pathology, vol. 157, no. 5, pp. 1415–1430, 2000.
[66] KEGG, “The (Kyoto Encyclopedia of Genes and Genomes)
PATHWAY Database. (Apoptosis),” http://www.genome.jp/
kegg/pathway/hsa/hsa04210.html.
[67] L. Galluzzi, I. Vitale, J. M. Abrams et al., “Molecular
deﬁnitions of cell death subroutines: recommendations of
the Nomenclature Committee on Cell Death 2012,” Cell
Death and Diﬀerentiation, vol. 19, no. 1, pp. 107–120, 2012.
[68] G. Groeger, C. Quiney, and T. G. Cotter, “Hydrogen peroxide
as a cell-survival signaling molecule,” Antioxidants and Redox
Signaling, vol. 11, no. 11, pp. 2655–2671, 2009.
[69] C.Velez-Pardo,G.Garcia-Ospina,andJ.M.DelRio,“Aβ[25–
35] peptide and iron promote apoptosis in lymphocytes by
a common oxidative mechanism: involvement of hydrogen
peroxide (H2O2), caspase-3, NF-kappa B, p53 and c-Jun,”
NeuroToxicol, vol. 23, no. 3, pp. 351–365, 2002.
[70] M. J. Del Rio, S. Moreno, G. Garcia-Ospina et al., “Autoso-
mal recessive juvenile Parkinsonism Cys212Tyr mutation in
parkin renders lymphocytes susceptible to dopamine- and
iron-mediated apoptosis,” Movement Disorders, vol. 19, no.
3, pp. 324–330, 2004.
[71] M. J. Del Rio and C. Velez-Pardo, “Monoamine neurotoxins-
induced apoptosis in lymphocytes by a common oxida-
tive stress mechanism: Involvement of hydrogen peroxide
(H2O2),caspase-3,andnuclearfactorkappa-B(NF-κB),p53,
c-Jun transcription factors,” Biochemical Pharmacology, vol.
63, no. 4, pp. 677–688, 2002.
[72] M. Jimenez Del Rio and C. Velez-Pardo, “Paraquat induces
apoptosis in human lymphocytes: protective and rescue
eﬀects of glucose, cannabinoids and insulin-like growth
factor-1,” Growth Factors, vol. 26, no. 1, pp. 49–60, 2008.
[73] I. C. Avila-Gomez, C. Velez-Pardo, and M. Jimenez-Del-Rio,
“Eﬀects of insulin-like growth factor-1 on rotenone-induced
apoptosis in human lymphocyte cells,” Basic and Clinical
PharmacologyandToxicology,vol.106,no.1,pp.53–61,2010.
[74] M. Jimenez Del Rio and C. Velez-Pardo, “17β-Estradiol
protects lymphocytes against dopamine and iron-induced
apoptosis by a genomic-independent mechanism - Impli-
cation in Parkinson’s disease,” General Pharmacology: The
Vascular System, vol. 35, no. 1, pp. 1–9, 2001.
[75] C. Velez-Pardo and M. Jimenez Del Rio, “Avoidance of
Aβ[25-35]/(H2O2)-inducedapoptosisinlymphocytesbythe
cannabinoid agonists CP55,940 and JWH-015 via receptor-
independent and PI3K-dependent mechanism: role of NF-
κB and p53,” Medicinal Chemistry, vol. 2, no. 5, pp. 471–479,
2006.
[76] C. Velez-Pardo, M. Jimenez-Del-Rio, S. Lores-Arnaiz, and J.
Bustamante, “Protective eﬀects of the synthetic cannabinoids
CP55,940 and JWH-015 on rat brain mitochondria upon
paraquat exposure,” Neurochemical Research, vol. 35, no. 9,
pp. 1323–1332, 2010.
[77] M. Jimenez Del Rio and C. Velez-Pardo, “Insulin-like growth
factor-1 prevents Aβ[25−−35]/ (H2O2)- induced apoptosis
in lymphocytes by reciprocal NF-κB activation and p53
inhibitionviaPI3K-dependentpathway,”Growth Factors,vol.
24, no. 1, pp. 67–78, 2006.
[78] S. Schoonbroodt, V. Ferreira, M. Best-Belpomme et al.,
“Crucial role of the amino-terminal tyrosine residue 42 and
the carboxylterminal PEST domain of I kappa B alpha in NF-
kappa B activation by an oxidative stress,” JI m m u n o l , vol.
164, no. 8, pp. 4292–4300, 2000.
[79] Y. Takada, A. Mukhopadhyay, G. C. Kundu, G. H. Maha-
beleshwar, S. Singh, and B. B. Aggarwal, “Hydrogen peroxide
activates NF-κB through tyrosine phosphorylation of IκBα
and serine phosphorylation of p65. Evidence for the involve-
mentofIκBαkinaseandSykprotein-tyrosinekinase,”Journal
of Biological Chemistry, vol. 278, no. 26, pp. 24233–24241,
2003.
[80] G. Gloire, E. Charlier, S. Rahmouni et al., “Restoration
of SHIP-1 activity in human leukemic cells modiﬁes NF-
κB activation pathway and cellular survival upon oxidative
stress,” Oncogene, vol. 25, no. 40, pp. 5485–5494, 2006.
[81] F. S. Lee, J. Hagler, Z. J. Chen, and T. Maniatis, “Activation
of the IκBα kinase complex by MEKK1, a kinase of the JNK
pathway,” Cell, vol. 88, no. 2, pp. 213–222, 1997.
[82] H. Wu and G. Lozano, “NF-κBa c t i v a t i o no fp 5 3 .Ap o t e n t i a l
mechanism for suppressing cell growth in response to stress,”
Journal of Biological Chemistry, vol. 269, no. 31, pp. 20067–
20074, 1994.
[83] I. A. Olovnikov, J. E. Kravchenko, and P. M. Chumakov,
“Homeostatic functions of the p53 tumor suppressor: reg-
ulation of energy metabolism and antioxidant defense,”
Seminars in Cancer Biology, vol. 19, no. 1, pp. 32–41, 2009.
[84] V. Borutaite, “Mitochondria as decision-makers in cell
death,”EnvironmentalandMolecularMutagenesis,vol.51,no.
5, pp. 406–416, 2010.
[85] F. Ricchelli, J. ˇ Sileikyte, and P. Bernardi, “Shedding light
on the mitochondrial permeability transition,” Biochimica et
Biophysica Acta, vol. 1807, no. 5, pp. 482–490, 2011.
[86] E. Norberg, S. Orrenius, and B. Zhivotovsky, “Mitochondrial
regulation of cell death: processing of apoptosis-inducing
factor (AIF),” Biochemical and Biophysical Research Commu-
nications, vol. 396, no. 1, pp. 95–100, 2010.
[87] H. Zou, Y. Li, X. Liu, and X. Wang, “An APAf-1 · cytochrome
C multimeric complex is a functional apoptosome that
activates procaspase-9,” Journal of Biological Chemistry, vol.
274, no. 17, pp. 11549–11556, 1999.
[88] R. U. J¨ a n i c k e ,M .L .S p r e n g a r t ,M .R .W a t i ,a n dA .G .
Porter, “Caspase-3 is required for DNA fragmentation and
morphological changes associated with apoptosis,” Journal of
Biological Chemistry, vol. 273, no. 16, pp. 9357–9360, 1998.
[89] M.Enari,H.Sakahira,H.Yokoyama,K.Okawa,A.Iwamatsu,
and S. Nagata, “A caspase-activated DNase that degrades
DNA during apoptosis, and its inhibitor ICAD,” Nature, vol.
391, no. 6662, pp. 43–50, 1998.
[90] V. J. Yuste, I. S´ anchez-L´ opez, C. Sol´ e et al., “The contribution
of apoptosis-inducing factor, caspase-activated DNase, and
inhibitor of caspase-activated DNase to the nuclear pheno-
type and DNA degradation during apoptosis,” Journal of
BiologicalChemistry,vol.280,no.42,pp.35670–35683,2005.
[91] H. Ichijo, E. Nishida, K. Irie et al., “Induction of apoptosis
by ASK1, a mammalian MAPKKK that activates SAPK/JNK
and p38 signaling pathways,” Science, vol. 275, no. 5296, pp.
90–94, 1997.
[92] M. Yan, T. Dai, J. C. Deak et al., “Activation of stress activated
protein kinase by MEKK1 phosphorylation of its activator
SEK1,” Nature, vol. 372, no. 6508, pp. 798–800, 1994.
[93] D. Yang, C. Tournier, M. Wysk et al., “Targeted disruption
of the MKK4 gene causes embryonic death, inhibition of
c-Jun NH2-terminal kinase activation, and defects in AP-1
transcriptional activity,” Proceedings of the National Academy
of Sciences of the United States of America,v o l .9 4 ,n o .7 ,p p .
3004–3009, 1997.
[94] A. Minden, A. Lin, T. Smeal et al., “c-Jun N-terminal phos-
phorylation correlates with activation of the JNK subgroup10 Oxidative Medicine and Cellular Longevity
but not the ERK subgroup of mitogen-activated protein
kinases,” Molecular and Cellular Biology, vol. 14, no. 10, pp.
6683–6688, 1994.
[95] D. N. Dhanasekaran and E. P. Reddy, “JNK signaling in
apoptosis,” Oncogene, vol. 27, no. 48, pp. 6245–6251, 2008.
[96] N. V. Oleinik, N. I. Krupenko, and S. A. Krupenko, “Cooper-
ation between JNK1 and JNK2 in activation of p53 apoptotic
pathway,” Oncogene, vol. 26, no. 51, pp. 7222–7230, 2007.
[97] M. Jim´ enez Del R´ ıo and C. V´ elez-Pardo, “Transition metal-
induced apoptosis in lymphocytes via hydroxyl radical gen-
eration, mitochondria dysfunction, and caspase-3 activation:
an in vitro model for neurodegeneration,” Archives of Medical
Research, vol. 35, no. 3, pp. 185–193, 2004.
[ 9 8 ] K .R .B a l e s ,Y .D u ,R .C .D o d e l ,G .M .Y a n ,E .H a m i l t o n - B yr d ,
and S. M. Paul, “The NF-κB/Rel family of proteins mediates
A β-induced neurotoxicity and glial activation,” Molecular
Brain Research, vol. 57, no. 1, pp. 63–72, 1998.
[99] D. Uberti, E. Yavin, S. Gil, K. R. Ayasola, N. Goldﬁnger, and
V. Rotter, “Hydrogen peroxide induces nuclear translocation
of p53 and apoptosis in cells of oligodendroglia origin,”
Molecular Brain Research, vol. 65, no. 2, pp. 167–175, 1999.
[100] N. Mar´ ın, B. Romero, F. Bosch-Morell et al., “β-Amyloid-
induced activation of Caspase-3 in primary cultures of rat
neurons,” Mechanisms of Ageing and Development, vol. 119,
no. 1-2, pp. 63–67, 2000.
[101] H. Panet, A. Barzilai, D. Daily, E. Melamed, and D. Oﬀen,
“Activation of nuclear transcription factor kappa B (NF-κB)
is essential for dopamine-induced apoptosis in PC12 cells,”
Journal of Neurochemistry, vol. 77, no. 2, pp. 391–398, 2001.
[102] C. M. Troy, S. A. Rabacchi, Z. Xu et al., “β-Amyloid-
inducedneuronalapoptosisrequiresc-JunN-terminalkinase
activation,”JournalofNeurochemistry,vol. 77,no. 1,pp. 157–
164, 2001.
[103] H. Aleyasin, S. P. Cregan, G. Iyirhiaro et al., “Nuclear factor-
κB modulates the p53 response in neurons exposed to DNA
damage,” Journal of Neuroscience, vol. 24, no. 12, pp. 2963–
2973, 2004.
[104] Y. Ohyagi, H. Asahara, D. H. Chui et al., “Intracellular Aβ42
activates p53 promoter: a pathway to neurodegeneration in
Alzheimer’s disease,” FASEB Journal, vol. 19, no. 2, pp. 255–
257, 2005.
[105] Y.-O. Son, Y. S. Jang, X. Shi, and J. C. Lee, “Activation of JNK
and c-Jun is involved in glucose oxidase-mediated cell death
of human lymphoma cells,” Molecules and Cells, vol. 28, no.
6, pp. 545–551, 2009.
[106] W. S. Choi, H. M. Klintworth, and Z. Xia, “JNK3-mediated
apoptotic cell death in primary dopaminergic neurons,”
Methods in Molecular Biology, vol. 758, pp. 279–292, 2011.
[107] A.Maheshwari,M.M.Misro,A.Aggarwal,R.K.Sharma,and
D. Nandan, “N-acetyl-L-cysteine counteracts oxidative stress
and prevents H2O2 induced germ cell apoptosis through
down-regulation of caspase-9 and JNK/c-Jun,” Molecular
Reproduction and Development, vol. 78, no. 2, pp. 69–79,
2011.
[108] S. Hunot, B. Brugg, D. Ricard et al., “Nuclear translocation
of NF-κb is increased in dopaminergic neurons of patients
with Parkinson disease,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 94, no. 14, pp.
7531–7536, 1997.
[109] Y. He, T. Lee, and S. K. Leong, “6-Hydroxydopamine induced
apoptosis of dopaminergic cells in the rat substantia nigra,”
Brain Research, vol. 858, no. 1, pp. 163–166, 2000.
[110] A. Hartmann, S. Hunot, P. P. Michel et al., “Caspase-3: a
vulnerability factor and ﬁnal eﬀe c t o ri na p o p t o t i cd e a t ho f
dopaminergic neurons in Parkinson’s disease,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 97, no. 6, pp. 2875–2880, 2000.
[111] C. Velez-Pardo, F. Lopera, and M. Jimenez Del Rio, “DNA
damage does not correlate with amyloid-β-plaques and neu-
roﬁbrillary tangles in familial Alzheimer’s disease presenilin-
1 [E280A] mutation,” Journal of Alzheimer’s Disease, vol. 2,
no. 1, pp. 47–57, 2000.
[112] J. H. Su, M. Zhao, A. J. Anderson, A. Srinivasan, and C. W.
Cotman, “Activated caspase-3 expression in Alzheimer’s and
aged control brain: correlation with Alzheimer pathology,”
Brain Research, vol. 898, no. 2, pp. 350–357, 2001.
[113] G. Garcia-Ospina, J. M. Del Rio, F. Lopera, and C. Velez-
Pardo, “Neuronal DNA damage correlates with a positive
detection of c-Jun, nuclear factor κB, p53 and Par-4 tran-
scription factors in Alzheimer’s disease,” Rev Neurol, vol. 36,
no. 11, pp. 1004–1010, 2003.
[114] A. Thakur, X. Wang, S. L. Siedlak, G. Perry, M. A. Smith,
and X. Zhu, “c-Jun phosphorylation in Alzheimer disease,”
Journal of Neuroscience Research, vol. 85, no. 8, pp. 1668–
1673, 2007.
[115] I. Ferrer, R. Blanco, M. Carmona et al., “Active, phos-
phorylation-dependent mitogen-activated protein kinase
(MAPK/ERK), stress-activated protein kinase/c-Jun N-
terminal kinase (SAPK/JNK), and p38 kinase expression in
Parkinson’s disease and Dementia with Lewy bodies,” Journal
of Neural Transmission, vol. 108, no. 12, pp. 1383–1396, 2001.
[116] M. E. McLellan, S. T. Kajdasz, B. T. Hyman, and B. J. Bacskai,
“In vivo imaging of reactive oxygen species speciﬁcally
associated with thioﬂavine S-positive amyloid plaques by
multiphoton microscopy,” Journal of Neuroscience, vol. 23,
no. 6, pp. 2212–2217, 2003.
[117] C. Wang, J. Li, Q. Liu et al., “Hydrogen-rich saline reduces
oxidative stress and inﬂammation by inhibit of JNK and
NF-κB activation in a rat model of amyloid-beta-induced
Alzheimer’s disease,” Neuroscience Letters, vol. 491, no. 2, pp.
127–132, 2011.
[118] M. Mogi, A. Togari, T. Kondo et al., “Caspase activities and
tumor necrosis factor receptor R1 (p55) level are elevated
in the substantia nigra from Parkinsonian brain,” Journal of
Neural Transmission, vol. 107, no. 3, pp. 335–341, 2000.
[119] M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu, “p53
protein, interferon-γ, and NF-κB levels are elevated in the
parkinsonian brain,” Neuroscience Letters, vol. 414, no. 1, pp.
94–97, 2007.
[120] Z. Q. Liang, Y. L. Li, X. L. Zhao et al., “NF-κBc o n t r i b u t e st o
6-hydroxydopamine-inducedapoptosisofnigraldopaminer-
gicneuronsthroughp53,”BrainResearch,vol.1145,no.1,pp.
190–203, 2007.
[121] L. Y. Li, X. L. Zhao, X. F. Fei, Z. L. Gu, Z. H. Qin, and Z.
Q.Liang,“Bilobalideinhibits6-OHDA-inducedactivationof
NF-κB and loss of dopaminergic neurons in rat substantia
nigra,” Acta Pharmacologica Sinica, vol. 29, no. 5, pp. 539–
547, 2008.
[122] A. M. Mu˜ noz, P. Rey, R. Soto-Otero, M. J. Guerra, and
J. L. Labandeira-Garcia, “Systemic Administration of N-
Acetylcysteine Protects Dopaminergic Neurons Against 6-
Hydroxydopamine-Induced Degeneration,” Journal of Neu-
roscience Research, vol. 76, no. 4, pp. 551–562, 2004.
[123] S. P. Braithwaite, R. S. Schmid, D. N. He et al., “Inhibition
of c-Jun kinase provides neuroprotection in a model of
Alzheimer’s disease,” Neurobiology of Disease, vol. 39, no. 3,
pp. 311–317, 2010.Oxidative Medicine and Cellular Longevity 11
[124] M. Jimenez-Del-Rio, A. Daza-Restrepo, and C. Velez-
Pardo, “The cannabinoid CP55,940 prolongs survival and
improves locomotor activity in Drosophila melanogaster
against paraquat: implications in Parkinson’s disease,” Neu-
roscience Research, vol. 61, no. 4, pp. 404–411, 2008.
[125] J. A. Botella, F. Bayersdorfer, F. Gmeiner, and S. Schneuwly,
“Modelling Parkinson’s Disease in Drosophila,” NeuroMolec-
ular Medicine, vol. 11, no. 4, pp. 268–280, 2009.
[126] M. Guo, “What have we learned from Drosophila models of
Parkinson’s disease?” Progress in Brain Research, vol. 184, no.
C, pp. 1–16, 2010.
[127] A. Chaudhuri, K. Bowling, C. Funderburk et al., “Interaction
of genetic and environmental factors in a Drosophila parkin-
sonism model,” Journal of Neuroscience, vol. 27, no. 10, pp.
2457–2467, 2007.
[128] M. Jimenez-Del-Rio, C. Guzman-Martinez, and C. Velez-
Pardo,“Theeﬀectsofpolyphenolsonsurvivalandlocomotor
activity in Drosophila melanogaster exposed to iron and
paraquat,” Neurochemical Research, vol. 35, no. 2, pp. 227–
238, 2010.
[129] H. F. Ortega-Arellano, M. Jimenez-Del-Rio, and C. Velez-
Pardo, “Life span and locomotor activity modiﬁcation by
glucose and polyphenols in Drosophila melanogaster chron-
ically exposed to oxidative stress-stimuli: implications in
Parkinson’s disease,” Neurochemical Research, vol. 36, no. 6,
pp. 1073–1086, 2011.
[130] B. Zhao, “Natural antioxidants protect neurons in
Alzheimer’s disease and parkinson’s disease,” Neurochemical
Research, vol. 34, no. 4, pp. 630–638, 2009.
[131] R.J.WilliamsandJ.P.E.Spencer,“Flavonoids,cognition,and
dementia: actions, mechanisms, and potential therapeutic
utility for Alzheimer disease,” Free Radical Biology and
Medicine, vol. 52, no. 1, pp. 35–45, 2012.
[132] L.Bonilla-Ramirez,M.Jimenez-Del-Rio,andC.Velez-Pardo,
“Acute and chronic metal exposure impairs locomotion
activity in Drosophila melanogaster:am o d e lt os t u d yP a r k i n -
sonism,” BioMetals, vol. 24, no. 6, pp. 1045–1057, 2011.
[133] J. Clark, E. L. Clore, K. Zheng, A. Adame, E. Masliah,
and D. K. Simon, “Oral N-Acetyl-cysteine attenuates loss of
dopaminergicterminalsinα-synucleinoverexpressingmice,”
PLoS One, vol. 5, no. 8, Article ID e12333, 2010.
[134] A. C. Badrick and C. E. Jones, “Reorganizing metals: the
use of chelating compounds as potential therapies for
metal-related neurodegenerative disease,” Current Topics in
Medicinal Chemistry, vol. 11, no. 5, pp. 543–552, 2011.
[135] M. Manczak, P. Mao, M. J. Calkins et al., “Mitochondria-
targeted antioxidants protect against amyloid-β toxicity in
Alzheimer’s disease neurons,” Journal of Alzheimer’s Disease,
vol. 20, supplement 2, pp. S609–S631, 2010.
[136] H. H. Szeto and P. W. Schiller, “Novel therapies targeting
inner mitochondrial membrane-from discovery to clinical
development,” Pharmaceutical Research, vol. 28, no. 11, pp.
2669–2679, 2011.
[137] J. S. Orange and M. J. May, “Cell penetrating peptide
inhibitors of nuclear factor-kappa B,” Cellular and Molecular
Life Sciences, vol. 65, no. 22, pp. 3564–3591, 2008.
[138] P. M. Flood, L. Qian, L. J. Peterson et al., “Transcriptional
factor NF-κb as a target for therapy in Parkinson’s disease,”
Parkinson’s Disease, vol. 2011, Article ID 216298, 8 pages,
2011.
[139] X. Zhu, Q. S. Yu, R. G. Cutler et al., “Novel p53 inactivators
with neuroprotective action: syntheses and pharmacological
evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole
and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives,”
Journal of Medicinal Chemistry, vol. 45, no. 23, pp. 5090–
5097, 2002.
[140] C. Hu, X. Li, W. Wang et al., “Design, synthesis, and bio-
logical evaluation of imidazoline derivatives as p53-MDM2
binding inhibitors,” Bioorganic and Medicinal Chemistry, vol.
19, no. 18, pp. 5454–5461, 2011.
[141] S. Mehan, H. Meena, D. Sharma, and R. Sankhla, “JNK:
a stress-activated protein kinase therapeutic strategies and
involvement in Alzheimer’s and various neurodegenerative
abnormalities,” JournalofMolecularNeuroscience,vol.43,no.
3, pp. 376–390, 2010.
[142] C. Polytarchou, M. Hatziapostolou, and E. Papadimitriou,
“Hydrogen peroxide stimulates proliferation and migration
ofhumanprostatecancercellsthroughactivationofactivator
protein-1 and up-regulation of the heparin aﬃn regulatory
peptide gene,” Journal of Biological Chemistry, vol. 280, no.
49, pp. 40428–40435, 2005.
[143] S. L. Payne, B. Fogelgren, A. R. Hess et al., “Lysyl oxidase
regulatesbreastcancercellmigrationandadhesionthrougha
hydrogen peroxide-mediated mechanism,” Cancer Research,
vol. 65, no. 24, pp. 11429–11436, 2005.
[144] I. Heirman, D. Ginneberge, R. Brigelius-Floh´ e et al., “Block-
ing tumor cell eicosanoid synthesis by GPx4 impedes tumor
growth and malignancy,” Free Radical Biology and Medicine,
vol. 40, no. 2, pp. 285–294, 2006.
[145] J. Wang and J. Yi, “Cancer cell killing via ROS: to increase or
decrease, that is a question,” Cancer Biology and Therapy, vol.
7, no. 12, pp. 1875–1884, 2008.
[146] J. Chen, M. Song, S. Yu et al., “Advanced glycation endprod-
ucts alter functions and promote apoptosis in endothelial
progenitor cells through receptor for advanced glycation
endproducts mediate overpression of cell oxidant stress,”
Molecular and Cellular Biochemistry, vol. 335, no. 1-2, pp.
137–146, 2010.
[147] R. Małek, K. K. Borowicz, M. Jargiełło, and S. J. Czuczwar,
“Role of nuclear factor kappaB in the central nervous
system,” Pharmacological Reports, vol. 59, no. 1, pp. 25–33,
2007.
[148] Z. H. Qin, L. Y. Tao, and X. Chen, “Dual roles of NF-
κB in cell survival and implications of NF-κB inhibitors in
neuroprotectivetherapy,”ActaPharmacologicaSinica,vol.28,
no. 12, pp. 1859–1872, 2007.
[149] N. G. Bazan, “Is NF-κB from astrocytes a decision maker of
neuronal life or death? (Commentary on Dvoriantchikova et
al.): commentary,” European Journal of Neuroscience, vol. 30,
no. 2, pp. 173–174, 2009.
[150] B. K. Bednarski, A. S. Baldwin, and H. J. Kim, “Addressing
reported pro-apoptotic functions of NF-κB: targeted inhi-
bition of canonical NF-κB enhances the apoptotic eﬀects of
doxorubicin,” PLoS One, vol. 4, no. 9, Article ID e6992, 2009.
[151] F. Wang, H. Li, H. Shi, and B. Sun, “Pro-apoptotic role of
nuclear factor-κB in adriamycin-induced acute myocardial
injury in rats,” Molecular Medicine Reports, vol. 5, no. 2, pp.
400–404, 2012.
[152] M. G. E. K. N. Isaac, R. Quinn, and N. Tabet, “Vitamin
E for Alzheimer’s disease and mild cognitive impairment,”
Cochrane Database of Systematic Reviews,n o .3 ,A r t i c l eI D
CD002854, 2008.
[153] G. J. Brewer, “Why vitamin e therapy fails for treatment of
Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 19,
no. 1, pp. 27–30, 2010.
[154] B. J. Snow, F. L. Rolfe, M. M. Lockhart et al., “A double-
blind, placebo-controlled study to assess the mitochondria-
targeted antioxidant MitoQ as a disease-modifying therapy12 Oxidative Medicine and Cellular Longevity
in Parkinson’s disease,” Movement Disorders, vol. 25, no. 11,
pp. 1670–1674, 2010.
[155] C. H. Pui, M. V. Relling, and J. R. Downing, “Mechanisms of
disease: acute lymphoblastic leukemia,” New England Journal
of Medicine, vol. 350, no. 15, pp. 1535–1548, 2004.
[156] A. R. Bonilla-Porras, M. Jimenez-Del-Rio, and C. Velez-
Pardo, “Vitamin K3 and vitamin C alone or in combination
induced apoptosis in leukemia cells by a similar oxidative
stress signalling mechanism,” Cancer Cell International, vol.
11, article 19, 2011.
[157] K.Jomova,Z.Jenisova,M.Feszterovaetal.,“Arsenic:toxicity,
oxidative stress and human disease,” Journal of Applied
Toxicology, vol. 31, no. 2, pp. 95–107, 2011.
[158] A. Meshkini and R. Yazdanparast, “Involvement of oxidative
stress in taxol-induced apoptosis in chronic myelogenous
leukemiaK562cells,”ExperimentalandToxicologicPathology.
In press.
[159] L. M. Bekris, C. E. Yu, T. D. Bird, and D. W. Tsuang, “Review
article: genetics of Alzheimer disease,” Journal of Geriatric
Psychiatry and Neurology, vol. 23, no. 4, pp. 213–227, 2010.
[160] L. M. Bekris, I. F. Mata, and C. P. Zabetian, “The genetics
of Parkinson disease,” Journal of Geriatric Psychiatry and
Neurology, vol. 23, no. 4, pp. 228–242, 2010.
[161] A. H. Schapira and M. Gegg, “Mitochondrial contribution
to Parkinson’s disease pathogenesis,” Parkinson’s Disease, vol.
2011, Article ID 159160, 7 pages, 2011.
[162] M. K. McCoy and M. R. Cookson, “Mitochondrial quality
control and dynamics in parkinson’s disease,” Antioxid Redox
Signal, vol. 16, no. 9, pp. 869–882, 2012.
[163] M. Vinish, A. Anand, and S. Prabhakar, “Altered oxidative
stress levels in Indian Parkinson’s disease patients with
PARK2 mutations,” Acta Biochimica Polonica, vol. 58, no. 2,
pp. 165–169, 2011.
[164] C. P. Ramsey and B. I. Giasson, “The E163K DJ-1 mutant
shows speciﬁc antioxidant deﬁciency,” Brain Research, vol.
1239, no. C, pp. 1–11, 2008.
[165] H.Ren,K.Fu,D.Wang,C.Mu,andG.Wang,“OxidizedDJ-1
interacts with the mitochondrial protein BCL-XL,” Journal of
BiologicalChemistry,vol.286,no.40,pp.35308–35317,2011.
[166] H. Y. Heo, J. M. Park, C. H. Kim, B. S. Han, K. S. Kim, and W.
Seol, “LRRK2 enhances oxidative stress-induced neurotoxic-
ity via its kinase activity,” Experimental cell research, vol. 316,
no. 4, pp. 649–656, 2010.
[167] H. Mohmmad Abdul, G. L. Wenk, M. Gramling, B. Hauss-
Wegrzyniak, and D. A. Butterﬁeld, “APP and PS-1 mutations
induce brain oxidative stress independent of dietary choles-
terol: implications for Alzheimer’s disease,” Neuroscience
Letters, vol. 368, no. 2, pp. 148–150, 2004.
[168] A. H. Mohmmad, R. Sultana, J. N. Keller, D. K. St Clair,
W. R. Markesbery, and D. A. Butterﬁeld, “Mutations in
amyloid precursor protein and presenilin-1 genes increase
the basal oxidative stress in murine neuronal cells and lead to
increased sensitivity to oxidative stress mediated by amyloid
beta-peptide (1-42), HO and kainic acid: implications for
Alzheimer’s disease,” Journal of Neurochemistry, vol. 96, no.
5, pp. 1322–1335, 2006.
[169] N. Ghebranious, B. Mukesh, P. F. Giampietro et al., “A pilot
study of gene/gene and gene/environment interactions in
Alzheimerdisease,”ClinicalMedicineandResearch,vol.9,no.
1, pp. 17–25, 2011.
[170] L.F.BurbullaandR.Kr¨ uger,“Convergingenvironmentaland
genetic pathways in the pathogenesis of Parkinson’s disease,”
Journal of the Neurological Sciences, vol. 306, no. 1-2, pp. 1–8,
2011.
[171] H. M. Gao and J. -S. Hong, “Gene-environment interactions:
keytounravelingthemysteryofParkinson’sdisease,”Progress
in Neurobiology, vol. 94, no. 1, pp. 1–19, 2011.
[172] A. Spivey, “Rotenone and paraquat linked to Parkinson’s
disease: human exposure study supports years of animal
studies,” Environmental Health Perspectives, vol. 119, no. 6,
p. A259, 2011.
[173] J. Sian-H¨ ulsmann, S. Mandel, M. B.H. Youdim, and P.
Riederer, “The relevance of iron in the pathogenesis of
Parkinson’s disease,” Journal of Neurochemistry, vol. 118, no.
6, pp. 939–957, 2011.
[174] Y. Qin, W. Zhu, C. Zhan et al., “Investigation on positive
correlation of increased brain iron deposition with cognitive
impairment in Alzheimer disease by using quantitative MR
R2’ mapping,” Journal of Huazhong University of Science and
Technology-Medical Science, vol. 31, no. 4, pp. 578–585, 2011.
[175] G. Gille and H. Reichmann, “Iron-dependent functions of
mitochondria—relation to neurodegeneration,” Journal of
Neural Transmission, vol. 118, no. 3, pp. 349–359, 2011.
[176] O. A. Levy, C. Malagelada, and L. A. Greene, “Cell death
pathways in Parkinson’s disease: proximal triggers, distal
eﬀectors, and ﬁnal steps,” Apoptosis, vol. 14, no. 4, pp. 478–
500, 2009.
[177] E. Bertrand, W. Lechowicz, G. M. Szpak, E. Lewandowska, J.
Dymecki, and T. Wierzba-Bobrowicz, “Limbic neuropathol-
ogy in idiopathic Parkinson’s disease with concomitant
dementia,” Folia Neuropathologica, vol. 42, no. 3, pp. 141–
150, 2004.
[178] A. Ramirez, A. Heimbach, J. Gr¨ undemann et al., “Hereditary
parkinsonism with dementia is caused by mutations in
ATP13A2, encoding a lysosomal type 5 P-type ATPase,”
Nature Genetics, vol. 38, no. 10, pp. 1184–1191, 2006.
[179] Y. Compta, L. Parkkinen, S. S. O’Sullivan et al., “Lewy- and
Alzheimer-type pathologies in Parkinson’s disease dementia:
which is more important?” Brain, vol. 134, no. 5, pp. 1493–
1505, 2011.
[180] A. Oda, A. Tamaoka, and W. Araki, “Oxidative stress up-
regulates presenilin 1 in lipid rafts in neuronal cells,” Journal
of Neuroscience Research, vol. 88, no. 5, pp. 1137–1145, 2010.
[181] D. -G. Jo, T. V. Arumugam, H. -N. Woo et al., “Evidence
thatγ-secretasemediatesoxidativestress-inducedβ-secretase
expressioninAlzheimer’sdisease,”NeurobiologyofAging,vol.
31, no. 6, pp. 917–925, 2010.
[182] K.Iijima-AndoandK.Iijima,“TransgenicDrosophilamodels
of Alzheimer’s disease and tauopathies,” Brain Structure and
Function, vol. 214, no. 2-3, pp. 245–262, 2010.
[183] J. M. Bonner and G. L. Boulianne, “Drosophila as a model to
study age-related neurodegenerative disorders: Alzheimer’s
disease,” Experimental Gerontology, vol. 46, no. 5, pp. 335–
339, 2011.
[184] J. Park, Y. Kim, and J. Chung, “Mitochondrial dysfunction
and Parkinson’s disease genes: insights from Drosophila,”
DMM Disease Models and Mechanisms,v o l .2 ,n o .7 - 8 ,p p .
336–340, 2009.
[185] A. J. Whitworth, “Drosophila models of Parkinson’s disease,”
Advances in Genetics, vol. 73, pp. 1–50, 2011.
[186] T. K. Sang, H. Y. Chang, G. M. Lawless et al., “A
Drosophila model of mutant human parkin-induced toxicity
demonstrates selective loss of dopaminergic neurons and
dependence on cellular dopamine,” Journal of Neuroscience,
vol. 27, no. 5, pp. 981–992, 2007.
[187] C. Wang, R. Lu, X. Ouyang et al., “Drosophila overexpress-
ing parkin R275W mutant exhibits dopaminergic neuronOxidative Medicine and Cellular Longevity 13
degeneration and mitochondrial abnormalities,” Journal of
Neuroscience, vol. 27, no. 32, pp. 8563–8570, 2007.
[188] I.E.Clark,M.W.Dodson,C.Jiangetal.,“Drosophilapink1is
required for mitochondrial function and interacts genetically
withparkin,”Nature,vol.441,no.7097,pp.1162–1166,2006.
[189] M. B. Feany and W. W. Bender, “A Drosophila model of
Parkinson’s disease,” Nature, vol. 404, no. 6776, pp. 394–398,
2000.
[190] Z. Liu, X.Wang, Y. Yu et al., “ADrosophila model for LRRK2-
linked parkinsonism,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 105, no. 7, pp.
2693–2698, 2008.
[191] E.Lavara-Culebras andN. Paricio,“Drosophila DJ-1mutants
aresensitivetooxidativestressandshowreducedlifespanand
motor deﬁcits,” Gene, vol. 400, no. 1-2, pp. 158–165, 2007.
[192] D. J. Moore, L. Zhang, J. Troncoso et al., “Association of DJ-
1 and parkin mediated by pathogenic DJ-1 mutations and
oxidative stress,” Human Molecular Genetics, vol. 14, no. 1,
pp. 71–84, 2005.
[193] M. Jendrach, S. Gispert, F. Ricciardi, M. Klinkenberg, R.
Schemm, and G. Auburger, “The mitochondrial kinase
PINK1, stress response and Parkinson’s disease,” Journal of
Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 481–486,
2009.
[194] D. C. Angeles, B. -H. Gan, L. Onstead et al., “Mutations in
LRRK2 increase phosphorylation of peroxiredoxin 3 exac-
erbating oxidative stress-induced neuronal death,” Human
Mutation, vol. 32, no. 12, pp. 1390–1397, 2011.
[195] H. -L. Wang, A. -H. Chou, A. -S. Wu et al., “PARK6 PINK1
mutants are defective in maintaining mitochondrial mem-
brane potential and inhibiting ROS formation of substantia
nigra dopaminergic neurons,” Biochimica et Biophysica Acta,
vol. 1812, no. 6, pp. 674–684, 2011.
[196] J. Park, S. B. Lee, S. Lee et al., “Mitochondrial dysfunction
in Drosophila PINK1 mutants is complemented by parkin,”
Nature, vol. 441, no. 7097, pp. 1157–1161, 2006.
[197] L.Y.Hao,B.I.Giasson,andN.M.Bonini,“DJ-1iscriticalfor
mitochondrial function and rescues PINK1 loss of function,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 21, pp. 9747–9752, 2010.
[198] C. A. Korey, “We hold these truths to be self-evident, that all
ﬂies and men are created equal: recent progress on human
disease models,” Fly, vol. 1, no. 2, pp. 118–122, 2007.
[199] J. M. Bertoni, J. P. Arlette, H. H. Fernandez et al., “North
American Parkinson’s and melanoma survey investigators.
increased melanoma risk in Parkinson disease: a prospective
clinicopathological study,” Archives of Neurology, vol. 67, no.
3, pp. 347–352, 2010.
[200] R. Liu, X. Gao, Y. Lu, and H. Chen, “Meta-analysis of
the relationship between Parkinson disease and melanoma,”
Neurology, vol. 76, no. 23, pp. 2002–2009, 2011.
[201] T. Pan, X. Li, and J. Jankovic, “The association between
Parkinson’s disease and melanoma,” International Journal of
Cancer, vol. 128, no. 10, pp. 2251–2260, 2011.
[202] S. Veeriah, B. S. Taylor, S. Meng et al., “Somatic mutations
of the Parkinson’s disease-associated gene PARK2 in glioblas-
toma and other human malignancies,” Nature Genetics, vol.
42, no. 1, pp. 77–82, 2010.
[203] C. Zhang, M. Lin, R. Wu et al., “Parkin, a p53 target
gene, mediates the role of p53 in glucose metabolism and
the Warburg eﬀect,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 108, no. 39, pp.
16259–16264, 2011.
[204] C. A. da Costa, C. Sunyach, E. Giaime et al., “Transcriptional
repression of p53 by parkin and impairment by mutations
associated with autosomal recessive juvenile Parkinson’s
disease,” Nature Cell Biology, vol. 11, no. 11, pp. 1370–1375,
2009.
[205] C. Alves da Costa and F. Checler, “Apoptosis in Parkinson’s
disease: is p53 the missing link between genetic and sporadic
Parkinsonism?” Cellular Signalling, vol. 23, no. 6, pp. 963–
968, 2010.
[206] G. Schneider and O. H. Kramer, “NFκB/p53 crosstalk-a
promising new therapeutic target,” Biochimica et Biophysica
Acta, vol. 1815, no. 1, pp. 90–103, 2011.
[207] K. B. Pandey and S. I. Rizvi, “Plant polyphenols as
dietary antioxidants in human health and disease,” Oxidative
Medicine and Cellular Longevity, vol. 2, no. 5, pp. 270–278,
2009.
[208] A. S. Darvesh, R. T. Carroll, A. Bishayee, W. J. Geldenhuys,
and C. J. Van Der Schyf, “Oxidative stress and Alzheimer’s
disease: dietary polyphenols as potential therapeutic agents,”
Expert Review of Neurotherapeutics, vol. 10, no. 5, pp. 729–
745, 2010.
[209] N. Ghosh, R. Ghosh, and S. C. Mandal, “Antioxidant
protection: apromising therapeutic intervention in neurode-
generative disease,” Free Radical Research, vol. 45, no. 8, pp.
888–905, 2011.
[210] B. Halliwell, “Dietary polyphenols: good, bad, or indiﬀerent
for your health?” Cardiovascular Research, vol. 73, no. 2, pp.
341–347, 2007.
[211] B. Halliwell, “Are polyphenols antioxidants or pro-oxidants?
What do we learn from cell culture and in vivo studies?”
Archives of Biochemistry and Biophysics, vol. 476, no. 2, pp.
107–112, 2008.
[212] S. Schaﬀer and B. Halliwell, “Do polyphenols enter the
brain and does it matter? Some theoretical and practical
considerations,” Genes & Nutrition, vol. 7, no. 2, pp. 99–109,
2012.
[213] F. Visioli, C. A. de la Lastra, C. Andres-Lacueva et al.,
“Polyphenols and human health: a prospectus,” Critical
Reviews in Food Science and Nutrition, vol. 51, no. 6, pp. 524–
546, 2011.
[214] K. Kieburtz and B. Ravina, “Why hasn’t neuroprotection
worked in Parkinson’s disease?” Nature Clinical Practice
Neurology, vol. 3, no. 5, pp. 240–241, 2007.